


INDEX

List of Tables

List of Abbreviations

List of Figures



Chapter	Title	Page
1	Introduction	1-5
	Research envisaged	3
	References	5
2	Literature Survey	6-87
2.1	Human respiratory system	7
	2.1.1 Pulmonary ventilation	8
	2.1.2 Major components of the lung - barriers to drug absorption	10
	2.1.3 Inhaler devices	17
	2.1.4 Factors influencing DPI formulation design	21
	2.1.5 Regulatory and Pharmacopoeial requirements	31
2.2	Liposomes	34
	2.2.1 Composition of liposomes	35
	2.2.2 Types of liposomes	38
	2.2.3 Methods of liposome preparation	38
	2.2.4 Characterization of liposomes	38
	2.2.5 Stability of liposomes	40
	2.2.6 Liposomes as drug delivery systems	44
2.3	Liposomes as pulmonary drug delivery systems	48
	2.3.1 Constraints of pulmonary drug delivery	49
	2.3.2 Controlled drug delivery to the lungs	51
	2.3.3 Pharmacokinetic and pharmacological studies	52
	2.3.4 Development of liposomal dosage form	57
2.4	Development of dry powder inhaler formulation	61
2.5	Drug profiles	64
	2.5.1 Amphotericin B	64
	2.5.2 Amikacin Sulphate	66
	References	70
3	Analytical methods	88-114
3.1	Physical characterization of liposomes	90
	3.1.1 Determination of shape and lamellarity	90
	3.1.2 Determination of size	90
3.2	Chemical characterization of liposomes	91

3.3	Analytical methods for AMK liposomes	91
3.3.1	Preparation of calibration curve for the estimation of AMK	91
3.3.2	Estimation of AMK in biological fluid and tissues	94
3.3.3	Preparation of calibration curve for the estimation of PC	97
3.3.4	Preparation of calibration curve for the estimation of Chol	99
3.3.5	Estimation of AMK, PC and CHOL in liposomes	101
3.3.6	Estimation of AMK from LDPI formulations	102
3.3.7	Estimation of AMK retention and vesicle size determination in liposomal DPI formulations during stability studies	103
3.3.8	Estimation of AMK in diffusion medium	104
3.3.9	Estimation of AMK in BAL and lung tissues	104
3.4	Analytical methods for AMB liposomes	105
3.4.1	Preparation of calibration curve for the estimation of AMB	105
3.4.2	Preparation of calibration curve for the estimation of AMB in biological fluids	107
3.4.3	Estimation of AMB, PC and CHOL in liposomes	109
3.4.4	Estimation of AMB from LDPI formulations	110
3.4.5	Estimation of AMB retention and vesicle size determination in liposomal DPI formulations during stability studies	111
3.4.6	Estimation of AMB in diffusion medium	111
3.4.7	Estimation of AMB in BAL and lung tissues	112
3.5	Results and discussion	112
	References	114
4	Preparation and characterization of liposomes	115-150
4.1	Experimental	116
4.1.1	Preparation of AMK liposomes	116
4.1.2	Preparation of AMB liposomes	120
4.2	Separation of unentrapped drug from liposomes	124
4.3	Chemical analysis	124
4.3.1	Percent drug entrapment	124
4.3.2	Percent drug unentrapped	125
4.4	Physical analysis	125
4.4.1	Trapped volume	125
4.4.2	Laser light scattering measurement	126
4.4.3	Photomicrography	126

4.5	Statistical analysis	126
4.6	Results and discussion	127
4.6.1	Influence of process parameters	132
4.6.2	Influence of formulation parameters	138
4.6.3	Characterization of liposomes	143
References		148
5	Preparation and characterization of liposomal Dry Powder Inhaler formulations	151-191
5.1	Lyophilization of liposomes	153
5.1.1	AMK liposomes	153
5.1.2	AMB liposomes	153
5.2	Method of preparation of liposomal Dry powder Inhaler formulations	154
5.3	AMK LDPI formulation	155
5.3.1	Effect of carrier addition	155
5.3.2	Effect of adding fines	155
5.3.3	Effect of adding sequence of fine	155
5.4	AMB LDPI formulation	156
5.4.1	Effect of carrier addition	156
5.4.2	Effect of adding fines	157
5.4.3	Effect of adding sequence of fine	157
5.5	Residual water content determination	157
5.6	Percent drug retained	158
5.7	Characterization of liposomal DPI formulations	158
5.7.1	Angle of repose	158
5.7.2	Compressibility index	158
5.7.3	Particle size determination	158
5.7.4	Photomicrography	159
5.7.5	SEM photomicrographs	159
5.7.6	Fine particle fraction	159
5.8	Statistical analysis	161
5.9	Results and discussion	162
5.9.1	Influence of formulation parameters	162
5.9.2	Optimization of LDPI formulation	168
5.9.3	Characterization of LDPI formulations	176
References		189
6	Stability studies	192-205
6.1	Method	193
6.2	Statistical analysis	194

6.3	Result and discussion	194
	References	205
7	In Vitro drug diffusion studies	206-221
7.1	Drug diffusion studies across artificial membrane	206
	7.1.1 Experimental setup	206
	7.1.2 Method	209
7.2	Statistical method	209
7.3	Results and discussion	211
	References	221
8	In Vivo instillation studies	222-235
8.1	Intratracheal instillation	223
8.2	Biological sampling	224
8.3	Statistical analysis	224
8.4	Result and discussion	225
	References	234
9	Summary and conclusion	235-250
9.1	Summary	235
9.2	Conclusion	247
	Research Publications	251